Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban for VTE prevention after total hip arthroplasty
NCT01203098Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of edoxaban in venous thromboembolism (VTE) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Percentage of Subjects With Venous Thromboembolism Events at 2 weeks. Started Jul 2008; status: completed.
02
Drugs
edoxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01203098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203098.